Literature DB >> 32279232

Lactobacillus brevis CD2: Fermentation Strategies and Extracellular Metabolites Characterization.

Alberto Alfano1, Filomena Perillo1, Alessandra Fusco2, Vittoria Savio2, Maria Michela Corsaro3, Giovanna Donnarumma2, Chiara Schiraldi4, Donatella Cimini5.   

Abstract

Functional foods and nutraceuticals frequently contain viable probiotic strains that, at certain titers, are considered to be responsible of beneficial effects on health. Recently, it was observed that secreted metabolites might play a key role in this respect, especially in immunomodulation. Exopolysaccharides produced by probiotics, for example, are used in the food, pharmaceutical, and biomedical fields, due to their unique properties. Lactobacillus brevis CD2 demonstrated the ability to inhibit oral pathogens causing mucositis and periodontal inflammation and to reduce Helycobacter pylori infections. Due to the lack of literature, for this strain, on the development of fermentation processes that can increase the titer of viable cells and associated metabolites to industrially attractive levels, different batch and fed-batch strategies were investigated in the present study. In particular, aeration was shown to improve the growth rate and the yields of lactic acid and biomass in batch cultures. The use of an exponential feeding profile in fed-batch experiments allowed to produce 9.3 ± 0.45 × 109 CFU/mL in 42 h of growth, corresponding to a 20-fold increase of viable cells compared with that obtained in aerated batch processes; moreover, also increased titers of exopolysaccharides and lactic acid (260 and 150%, respectively) were observed. A purification process based on ultrafiltration, charcoal treatment, and solvent precipitation was applied to partially purify secreted metabolites and separate them into two molecular weight fractions (above and below 10 kDa). Both fractions inhibited growth of the known gut pathogen, Salmonella typhimurium, demonstrating that lactic acid plays a major role in pathogen growth inhibition, which is however further enhanced by the presence of Lact. brevis CD2 exopolysaccharides. Finally, the EPS produced from Lact. brevis CD2 was characterized by NMR for the first time up to date.

Entities:  

Keywords:  Antimicrobial activity; Exopolysaccharides; Fed-batch processes; Lactobacillus brevis; Probiotic; Ultrafiltration membrane

Mesh:

Substances:

Year:  2020        PMID: 32279232     DOI: 10.1007/s12602-020-09651-w

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  1 in total

1.  Limosilactobacillus fermentum from buffalo milk is suitable for potential biotechnological process development and inhibits Helicobacter pylori in a gastric epithelial cell model.

Authors:  Sergio D'ambrosio; Michela Ventrone; Alessandra Fusco; Angela Casillo; Azza Dabous; Marcella Cammarota; Maria Michela Corsaro; Giovanna Donnarumma; Chiara Schiraldi; Donatella Cimini
Journal:  Biotechnol Rep (Amst)       Date:  2022-04-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.